Elizabeth Klein has now joined our team of equity research analysts. Elizabeth, a highly rated Biosciences investment analyst, previously worked N+1 Singer where she focused on the Healthcare and IP Commercialisation sectors. Before that she was at Teathers, Bridgewell, R.W. Baird and Dresdner Kleinwort Benson. Andy Edmond, CEO, says "having had the pleasure of working with Elizabeth in the past i am really pleased that she is bringing her experience and insight to ED".
Register to be first
Get research on the companies that interest you straight to your inbox
